94
Participants
Start Date
May 20, 2012
Primary Completion Date
January 19, 2018
Study Completion Date
January 19, 2018
Ataluren
Oral powder for suspension
Royal Children's Hospital, Parkville
Institute For Neuromuscular Research, The Children's Hospital at Westmead, Westmead
University Hospital KU Leuven, Leuven
Alberta Children's Hospital, Calgary
British Columbia Children's Hospital, Vancouver
Children's Hospital of Western Ontario, London
Hôpital d'Enfants CHU Timone, Marseille
Laboratoire d'Exploration Fonctionnelles, Nantes
Groupe Hospitalier La Pitie-Salpetriere, Paris
University of Essen - Clinic for Children, Essen
University Hospital, Freiburg im Breisgau
Hadassah Medical Center, Hebrew University Hospital, Jerusalem
Ospedale Maggiore Policlinico in Milan, Milan
Ospedale Pediatrico Bambino Gesu, Rome
U.O. Complessa di Neuropsichiatria Infantile, Rome
Hospital Sant Joan de déu, Barcelona
Hospital Universitari La Fe, Valencia
Queen Silvia Children's Hospital, Gothenburg
Astrid Lindgren Pediatric Hospital, Stockholm
Great Ormond Street Hospital, London
University of Newcastle Institute of Human Genetics, Newcastle upon Tyne
Lead Sponsor
PTC Therapeutics
INDUSTRY